Diego Viasus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1632985/publications.pdf

Version: 2024-02-01

206121 182225 2,772 60 30 51 citations h-index g-index papers 62 62 62 4488 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Clinical features and prognostic factors of adults with COVID-19 admitted to intensive care units in Colombia: A multicentre retrospective study during the first wave of the pandemic. Acta Colombiana De Cuidado Intensivo, 2022, 22, 95-99.	0.1	6
2	Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities. Occupational and Environmental Medicine, 2022, 79, 388-395.	1.3	11
3	Epidemiology of 4963 deaths associated with COVIDâ€19 during three pandemic waves in a Latin American city with a high mortality rate, 2020–2021. Tropical Medicine and International Health, 2022, 27, 158-164.	1.0	7
4	Legionnaires' Disease: Update on Diagnosis and Treatment. Infectious Diseases and Therapy, 2022, 11, 973-986.	1.8	38
5	Burden of invasive pneumococcal disease (IPD) over a 10-year period in BogotÃ;, Colombia. International Journal of Infectious Diseases, 2021, 105, 32-39.	1.5	12
6	Unexpected high frequency of early mortality in COVID â€19: a singleâ€centre experience during the first wave of the pandemic. Internal Medicine Journal, 2021, 51, 102-105.	0.5	2
7	Effects of age and comorbidities on serum levels of inflammatory markers in communityâ€acquired pneumonia. European Journal of Clinical Investigation, 2021, 51, e13480.	1.7	4
8	Diabetic Ketoacidosis Precipitated by COVID-19 in Patients Without Respiratory Symptoms: Case Reports. Cureus, 2020, 12, e10031.	0.2	6
9	Dengue, chikungunya and zika virus coinfection: results of the national surveillance during the zika epidemic in Colombia. Epidemiology and Infection, 2019, 147, e77.	1.0	60
10	Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia: a systematic review and meta-analysis. BMC Infectious Diseases, 2019, 19, 403.	1.3	34
11	Urinary antigen testing in community-acquired pneumonia in adults: an update. Expert Review of Anti-Infective Therapy, 2019, 17, 107-115.	2.0	27
12	Renal involvement in fatal cases of chikungunya virus infection. Journal of Clinical Virology, 2018, 103, 16-18.	1.6	29
13	Pharmacotherapy for community-acquired pneumonia in the elderly. Expert Opinion on Pharmacotherapy, 2017, 18, 957-964.	0.9	11
14	Antibiotic stewardship in community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2017, 15, 351-359.	2.0	28
15	Solithromycin for the treatment of community-acquired bacterial pneumonia. Expert Review of Respiratory Medicine, 2017, 11, 5-12.	1.0	14
16	Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. Journal of Antimicrobial Chemotherapy, 2017, 72, 547-5553.	1.3	44
17	Epidemiological, clinical, diagnostic and economic features of an immigrant population of chronic schistosomiasis sufferers with long-term residence in a non-endemic country (North Metropolitan) Tj ETQq1 1 0.).78 43 14 r	gB⊉¦Overlock
18	Chikungunya Pathogenesis: From the Clinics to the Bench. Journal of Infectious Diseases, 2016, 214, S446-S448.	1.9	34

#	Article	IF	CITATIONS
19	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09â€related pneumonia: an individual participant data metaâ€analysis. Influenza and Other Respiratory Viruses, 2016, 10, 192-204.	1.5	54
20	Chikungunya in the region of the Americas. A challenge for rheumatologists and health care systems. Clinical Rheumatology, 2016, 35, 2381-2385.	1.0	25
21	Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis. Journal of Infection, 2016, 72, 273-282.	1.7	84
22	Clinical and histopathological features of fatal cases with dengue and chikungunya virus co-infection in Colombia, 2014 to 2015. Eurosurveillance, 2016, 21, .	3.9	41
23	Fatal cases of Chikungunya virus infection in Colombia: Diagnostic and treatment challenges. Journal of Clinical Virology, 2015, 69, 27-29.	1.6	59
24	The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. BMJ Open, 2015, 5, e006251-e006251.	0.8	42
25	Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial. PLoS ONE, 2015, 10, e0140202.	1.1	10
26	Management of community-acquired pneumonia in older adults. Therapeutic Advances in Infectious Disease, 2014, 2, 3-16.	1.1	68
27	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respiratory Medicine,the, 2014, 2, 395-404.	5. 2	527
28	Impact of pre-hospital antibiotic use on community-acquired pneumonia. Clinical Microbiology and Infection, 2014, 20, O531-O537.	2.8	9
29	Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. Journal of Infection, 2014, 68, 534-541.	1.7	34
30	Clinical Features, Etiology and Outcomes of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e105854.	1.1	45
31	Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 415-423.	1.7	97
32	Prediction of prognosis by markers in community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2013, 11, 917-929.	2.0	20
33	Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 27-33.	1.7	76
34	Community-acquired pneumonia during the first post-pandemic influenza season: A prospective, multicentre cohort study. Journal of Infection, 2013, 67, 185-193.	1.7	25
35	Clinical Features, Etiology, and Outcomes of Community-Acquired Pneumonia in Patients With Diabetes Mellitus. Medicine (United States), 2013, 92, 42-50.	0.4	35
36	Pathogenesis of invasive fungal infections. Current Opinion in Infectious Diseases, 2013, 26, 270-276.	1.3	85

#	Article	IF	Citations
37	Advances in antibiotic therapy for community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 2013, 19, 209-215.	1.2	15
38	Community-Acquired Legionella pneumophila Pneumonia. Medicine (United States), 2013, 92, 51-60.	0.4	102
39	Rainfall Is a Risk Factor for Sporadic Cases of Legionella pneumophila Pneumonia. PLoS ONE, 2013, 8, e61036.	1.1	47
40	Effect of Statin Use on Outcomes of Adults with Candidemia. PLoS ONE, 2013, 8, e77317.	1.1	15
41	Prognosis of 2009 A(H1N1) Influenza in Hospitalized Pregnant Women in a Context of Early Diagnosis and Antiviral Therapy. Antiviral Therapy, 2012, 17, 719-728.	0.6	8
42	Influenza A(H1N1)pdm09-related pneumonia and other complications. Enfermedades Infecciosas Y MicrobiologÃa ClÂnica, 2012, 30, 43-48.	0.3	15
43	Influenza A(H1N1)pdm09: beyond the pandemic. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 54-57.	0.3	5
44	Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia. Clinical Microbiology and Infection, 2012, 18, 1149-1155.	2.8	30
45	Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season. Clinical Microbiology and Infection, 2012, 18, E55-E62.	2.8	44
46	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 547-556.	1.3	31
47	Pandemic 2009 A(H1N1) Infection Requiring Hospitalization of Elderly Spanish Adults. Journal of the American Geriatrics Society, 2012, 60, 740-744.	1.3	4
48	Pneumonia Complicating Pandemic (H1N1) 2009. Medicine (United States), 2011, 90, 328-336.	0.4	32
49	Community-Acquired Pneumonia in Patients With Liver Cirrhosis. Medicine (United States), 2011, 90, 110-118.	0.4	78
50	Timing of Oseltamivir Administration and Outcomes in Hospitalized Adults With Pandemic 2009 Influenza A(H1N1) Virus Infection. Chest, 2011, 140, 1025-1032.	0.4	57
51	A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with communityâ€acquired pneumonia. Respirology, 2011, 16, 1119-1126.	1.3	32
52	Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clinical Microbiology and Infection, 2011, 17, 738-746.	2.8	93
53	Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clinical Microbiology and Infection, 2011, 17, 1659-1665.	2.8	81
54	Effect of statins on outcomes in immunosuppressed patients with bloodstream infection. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 77-82.	1.3	9

#	ARTICLE	IF	CITATION
55	Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. Journal of Infection, 2011, 62, 193-199.	1.7	64
56	Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 2899-2906.	0.4	88
57	Statins for community-acquired pneumonia: current state of the science. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 143-152.	1.3	42
58	Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax, 2010, 65, 77-81.	2.7	97
59	Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. Aids, 2010, 24, 2461-2467.	1.0	38
60	Early, short and long-term mortality in community-acquired pneumonia. Annals of Research Hospitals, 0, 2, 5-5.	0.0	9